Dermira Inc. (NASDAQ:DERM)‘s stock had its “buy” rating reissued by analysts at Leerink Swann in a report released on Wednesday.
A number of other analysts have also recently issued reports on DERM. Needham & Company LLC reissued a “buy” rating and set a $46.00 price objective on shares of Dermira in a research report on Wednesday, September 21st. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $41.00.
Shares of Dermira (NASDAQ:DERM) traded up 0.930% during midday trading on Wednesday, reaching $35.255. The company’s stock had a trading volume of 36,524 shares. The stock’s market capitalization is $1.25 billion. The stock’s 50-day moving average is $33.21 and its 200 day moving average is $29.50. Dermira has a 12 month low of $17.42 and a 12 month high of $36.16.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, analysts expect that Dermira will post ($3.46) earnings per share for the current fiscal year.
In other Dermira news, CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $33.19, for a total value of $365,090.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief financial officer now directly owns 14,375 shares of the company’s stock, valued at approximately $433,406.25. The disclosure for this sale can be found here. 17.30% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Strs Ohio raised its position in Dermira by 72.6% in the second quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 5,300 shares during the last quarter. Eagle Asset Management Inc. raised its position in Dermira by 4.3% in the second quarter. Eagle Asset Management Inc. now owns 1,344,721 shares of the biopharmaceutical company’s stock worth $39,333,000 after buying an additional 55,991 shares during the last quarter. Hamilton Lane Advisors LLC raised its position in Dermira by 179.5% in the second quarter. Hamilton Lane Advisors LLC now owns 34,615 shares of the biopharmaceutical company’s stock worth $1,099,000 after buying an additional 22,229 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in Dermira during the first quarter worth approximately $2,482,000. Finally, Geode Capital Management LLC raised its position in Dermira by 7.8% in the first quarter. Geode Capital Management LLC now owns 123,424 shares of the biopharmaceutical company’s stock worth $2,552,000 after buying an additional 8,952 shares during the last quarter. 82.46% of the stock is owned by institutional investors.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.